Candel Therapeutics, Inc.
CADLDrugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Sep 26, 2026
14dMarket Overview
Stock performance and key metrics
3 upcoming, 1 past
Conference — Aglatimagene Besadenovec
For cancer. Candel Therapeutics announced acceptance of an abstract for poster presentation of extended Phase 3 data on aglatimagene besadenovec at the 2026 ASTRO Annual Meeting in September 2026.
Source2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How CADL's past catalysts played out
aglatimagene besadenovec
Prostate Cancer
Valacyclovir
Non-squamous, Non-Small Cell Lung Cancer
aglatimagene besadenovec + valacyclovir
Prostate Cancer Patients Treated by Radiotherapy
CAN-2409
Malignant Glioma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
aglatimagene besadenovec | Phase 3 | Prostate Cancer | - | - |
Valacyclovir | Phase 3 | Non-squamous, Non-Small Cell Lung Cancer | - | - |
aglatimagene besadenovec + valacyclovir | Phase 3 | Prostate Cancer Patients Treated by Radiotherapy | - | - |
CAN-2409 | Phase 2 | Malignant Glioma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Candel Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Candel Therapeutics, Inc.'s (CADL) pipeline across Phase 3, Phase 2. Its lead program is aglatimagene besadenovec (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Candel Therapeutics, Inc.'s next FDA catalyst?→
Candel Therapeutics, Inc.'s (CADL) next tracked catalyst is a Conference expected September 26, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CADL biotech catalysts?→
Add CADL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Candel Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.